Application 204790

Type: NDA
Sponsor: VIIV HLTHCARE

Application Products#

Product, Drug, Ingredient table
Product	Drug	Ingredient	Form	Strength	Reference drug	Reference standard
001	TIVICAY	DOLUTEGRAVIR SODIUM	TABLET;ORAL	EQ 50MG BASE	Yes	Yes
002	TIVICAY	DOLUTEGRAVIR SODIUM	TABLET;ORAL	EQ 10MG BASE	Yes	No
003	TIVICAY	DOLUTEGRAVIR SODIUM	TABLET;ORAL	EQ 25MG BASE	Yes	No

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N204790-001	TIVICAY	DOLUTEGRAVIR SODIUM	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12
N204790-002	TIVICAY	DOLUTEGRAVIR SODIUM	EQ 10MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL	RLD	2016-06-09
N204790-003	TIVICAY	DOLUTEGRAVIR SODIUM	EQ 25MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET / ORAL	RLD	2016-06-09

Orange Book patents#

Current patent rows page 1 of 1 · 12 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Coverage / status	Submission date
N204790-001	8129385	2027-10-05	Drug substance, Drug product	2013-08-27
N204790-001	8129385*PED	2028-04-05	Pediatric extension
N204790-001	9242986	2029-12-08	Drug substance, Drug product	2016-03-10
N204790-001	9242986*PED	2030-06-08	Pediatric extension
N204790-002	8129385	2027-10-05	Drug substance, Drug product	2016-06-15
N204790-002	8129385*PED	2028-04-05	Pediatric extension
N204790-002	9242986	2029-12-08	Drug substance, Drug product	2016-06-15
N204790-002	9242986*PED	2030-06-08	Pediatric extension
N204790-003	8129385	2027-10-05	Drug substance, Drug product	2016-06-15
N204790-003	8129385*PED	2028-04-05	Pediatric extension
N204790-003	9242986	2029-12-08	Drug substance, Drug product	2016-06-15
N204790-003	9242986*PED	2030-06-08	Pediatric extension

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 2 of 4 · 132 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N204790-003	TIVICAY	EQ 25MG BASE	TABLET / ORAL	RLD	2016-06-09	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N204790-001	TIVICAY	EQ 50MG BASE	TABLET / ORAL	RLD, RS	2013-08-12	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	N204790-002	TIVICAY	EQ 10MG BASE	TABLET / ORAL	RLD	2016-06-09	`c0c555d07b60…`

Observed Orange Book patent history#

Patent history page 1 of 11 · 402 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Coverage / status	Submission date	Source SHA-256
2026-10-15 13:18:30	2026-09	N204790-001	8129385	2027-10-05	Drug substance, Drug product	2013-08-27	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-001	8129385*PED	2028-04-05	Pediatric extension		`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-001	9242986	2029-12-08	Drug substance, Drug product	2016-03-10	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-001	9242986*PED	2030-06-08	Pediatric extension		`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-002	8129385	2027-10-05	Drug substance, Drug product	2016-06-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-002	8129385*PED	2028-04-05	Pediatric extension		`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-002	9242986	2029-12-08	Drug substance, Drug product	2016-06-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-002	9242986*PED	2030-06-08	Pediatric extension		`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-003	8129385	2027-10-05	Drug substance, Drug product	2016-06-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-003	8129385*PED	2028-04-05	Pediatric extension		`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-003	9242986	2029-12-08	Drug substance, Drug product	2016-06-15	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	N204790-003	9242986*PED	2030-06-08	Pediatric extension		`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	N204790-001	8129385	2027-10-05	Drug substance, Drug product	2013-08-27	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-001	8129385*PED	2028-04-05	Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-001	9242986	2029-12-08	Drug substance, Drug product	2016-03-10	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-001	9242986*PED	2030-06-08	Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-002	8129385	2027-10-05	Drug substance, Drug product	2016-06-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-002	8129385*PED	2028-04-05	Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-002	9242986	2029-12-08	Drug substance, Drug product	2016-06-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-002	9242986*PED	2030-06-08	Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-003	8129385	2027-10-05	Drug substance, Drug product	2016-06-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-003	8129385*PED	2028-04-05	Pediatric extension		`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-003	9242986	2029-12-08	Drug substance, Drug product	2016-06-15	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N204790-003	9242986*PED	2030-06-08	Pediatric extension		`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N204790-001	8129385	2027-10-05	Drug substance, Drug product	2013-08-27	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-001	8129385*PED	2028-04-05	Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-001	9242986	2029-12-08	Drug substance, Drug product	2016-03-10	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-001	9242986*PED	2030-06-08	Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-002	8129385	2027-10-05	Drug substance, Drug product	2016-06-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-002	8129385*PED	2028-04-05	Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-002	9242986	2029-12-08	Drug substance, Drug product	2016-06-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-002	9242986*PED	2030-06-08	Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-003	8129385	2027-10-05	Drug substance, Drug product	2016-06-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-003	8129385*PED	2028-04-05	Pediatric extension		`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-003	9242986	2029-12-08	Drug substance, Drug product	2016-06-15	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N204790-003	9242986*PED	2030-06-08	Pediatric extension		`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N204790-001	8129385	2027-10-05	Drug substance, Drug product	2013-08-27	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N204790-001	8129385*PED	2028-04-05	Pediatric extension		`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N204790-001	9242986	2029-12-08	Drug substance, Drug product	2016-03-10	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N204790-001	9242986*PED	2030-06-08	Pediatric extension		`011fe1cb6892…`

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2019-12-13 00:20 UTC	2019-12	N204790-001	I-758	2020-11-21	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N204790-002	I-758	2020-11-21	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N204790-003	I-758	2020-11-21	`74a2ff9319b5…`
2020-12-22 03:56 UTC	2020-12	N204790-001	I-758	2020-11-21	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N204790-002	I-758	2020-11-21	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N204790-003	I-758	2020-11-21	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N204790-001	I-758	2020-11-21	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	N204790-002	I-758	2020-11-21	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	N204790-003	I-758	2020-11-21	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	N204790-001	I-758	2020-11-21	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N204790-002	I-758	2020-11-21	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N204790-003	I-758	2020-11-21	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N204790-001	I-758	2020-11-21	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N204790-002	I-758	2020-11-21	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N204790-003	I-758	2020-11-21	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N204790-001	I-758	2020-11-21	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N204790-002	I-758	2020-11-21	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N204790-003	I-758	2020-11-21	`ea99ee380514…`

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Tivicay	DOLUTEGRAVIR SODIUM	ST. MARY'S MEDICAL PARK PHARMACY	485bc9db-8665-9f5a-e063-6394a90a7921	2026-05-22	Warnings, Adverse reactions	Exact identifier application applno (NDA): 204790 application number: NDA204790

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 38 matching rows.

NDC, Name, Nonproprietary name table
NDC	Name	Nonproprietary name	Labeler	Marketing category	Status
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-226	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-227	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
49702-228	Tivicay	dolutegravir sodium	ViiV Healthcare Company	NDA	Current
50090-1355	Tivicay	dolutegravir sodium	A-S Medication Solutions	NDA	Current
53808-1130	Tivicay	dolutegravir sodium	DOH CENTRAL PHARMACY	NDA	Current
67296-1818	Tivicay	dolutegravir sodium	RedPharm Drug, Inc.	NDA	Current
70518-1487	Tivicay	dolutegravir sodium	REMEDYREPACK INC.	NDA	Current
70518-1487	Tivicay	dolutegravir sodium	REMEDYREPACK INC.	NDA	Current
70518-1487	Tivicay	dolutegravir sodium	REMEDYREPACK INC.	NDA	Current
70518-1487	Tivicay	dolutegravir sodium	REMEDYREPACK INC.	NDA	Current
70518-1487	Tivicay	dolutegravir sodium	REMEDYREPACK INC.	NDA	Current

Documents#

Document, Submission type, Date table
Document	Submission type	Date
83982	SUPPL	2025-10-29
83975	SUPPL	2025-10-29
78170	SUPPL	2024-04-19
78161	SUPPL	2024-04-19
72298	SUPPL	2022-10-11
72285	SUPPL	2022-10-11
68062	SUPPL	2021-07-13
68050	SUPPL	2021-07-12
66863	SUPPL	2021-03-25
66855	SUPPL	2021-03-24
63573	SUPPL	2020-06-16
63565	SUPPL	2020-06-15
62331	SUPPL	2020-03-25
62325	SUPPL	2020-03-25
60691	SUPPL	2019-10-28
60668	SUPPL	2019-10-25
55444	SUPPL	2018-09-12
55443	SUPPL	2018-09-12
55417	SUPPL	2018-09-10
55416	SUPPL	2018-09-10
50499	SUPPL	2017-11-27
50480	SUPPL	2017-11-24
47763	SUPPL	2017-03-29
47734	SUPPL	2017-03-28
32593	SUPPL	2016-06-10
19602	SUPPL	2016-06-10
40423	SUPPL	2016-04-29
32592	SUPPL	2016-04-26
10396	SUPPL	2015-08-10
19601	SUPPL	2015-08-07
19600	SUPPL	2015-01-08
32591	SUPPL	2014-12-24
40422	SUPPL	2014-05-13
32590	SUPPL	2014-05-13
43479	ORIG	2013-09-13
24481	ORIG	2013-09-13
10395	ORIG	2013-08-20
19599	ORIG	2013-08-19
54054	SUPPL	1900-01-01
52619	SUPPL	1900-01-01
52618	SUPPL	1900-01-01
52616	ORIG	1900-01-01
52615	ORIG	1900-01-01
52614	ORIG	1900-01-01